Chronic lymphocytic leukaemia trials in Spain

In Spain 43 Also abroad 308

43 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A long-term follow-up study for patients treated with Galapagos CAR T cell therapies
Where
Barcelona
Age
18 years and over
People
309 worldwide
Run by
Lakefront Biotherapeutics
See details and how to join2023-510173-34-00 · EU 2023-510173-34-00
Phase 3Taking people
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Where
Barcelona, Girona, Madrid, Majadahonda, Marbella, Pamplona, Santander, Sevilla
Age
18 years and over
People
737 worldwide
Run by
Loxo Oncology, Inc.
See details and how to joinNCT05254743 · EU 2023-507699-38-00
Phase 1Taking people
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Where
Madrid, Pamplona
Age
18 years and over
People
85 worldwide
Run by
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
See details and how to joinNCT06980116 · EU 2024-516869-36-00
Phase 1Taking people
Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
Where
Barcelona
Age
18 years and over
People
54 worldwide
Run by
F. Hoffmann-La Roche AG
See details and how to join2022-501876-24-00 · EU 2022-501876-24-00
Phase 3Taking people
A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
Where
Girona
Age
18 years and over
People
344 worldwide
Run by
Ascentage Pharma Group Inc.
See details and how to joinNCT06319456 · EU 2024-514084-26-00
Phase 2Taking people
A multicenter, phase 2 randomized, open label study to evaluate the efficacy and security of zanubrutinib in combination with obinutuzumab in previously untreated patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) (GELLC-10-ZANUBIO)
Where
Badalona, Barcelona, Córdoba, Las Palmas De Gran Canaria, Madrid, Málaga, Marbella, Oviedo, Salamanca, Santander, Sevilla, Valencia, Vigo
Age
18 years and over
People
106
Run by
Pethema Fundacion
See details and how to join2023-504647-14-00 · EU 2023-504647-14-00
Phase 1Taking people
A Study to Test How Safe, Effective and How the Body Responds to the Combination of Mosunetuzumab and Pirtobrutinib Together to Treat Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Where
Barcelona, Madrid, Pamplona
Age
18 years and over
People
22 worldwide
Run by
F. Hoffmann-La Roche AG
See details and how to join2024-514152-32-00 · EU 2024-514152-32-00
Phase 1Taking people
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Where
Barcelona, Gijón, Madrid
Age
18 years and over
People
572 worldwide
Run by
Nurix Therapeutics, Inc.
See details and how to joinNCT05131022 · EU 2023-510541-25-00
Phase 1/2Taking people
Phase 1/2 multicenter, open-label, dose-escalation study of IDP-121 in patients with relapsed/refractory hematologic malignancies (CASSANDRA)
Where
Barcelona, L'Hospitalet de Llobregat, Madrid, Majadahonda, Murcia, Salamanca, Santander, Sevilla, Valencia, Zaragoza
Age
18 years and over
People
62
Run by
Idp Discovery Pharma S.L.
See details and how to join2024-519194-19-00 · EU 2024-519194-19-00
Phase 2Taking people
Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Where
Alicante, Barcelona, Córdoba, Las Palmas de Gran Canaria, Madrid, Málaga, Marbella, Oviedo, Palma de Mallorca, Pamplona, Salamanca, Santander, Seville, Valencia, Vigo
Age
18 years and over
People
106
Run by
PETHEMA Foundation
See details and how to joinNCT06544785
Phase 3Taking people
Global Trial in APG2575 for Patients With CLL/SLL
Where
Barcelona, Madrid, Palma, Santander, Valencia
Age
18 years to 99 years
People
400 worldwide
Run by
Ascentage Pharma Group Inc.
See details and how to joinNCT06104566 · EU 2023-508005-24-00
Phase 2Taking people
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Where
Madrid
Age
18 years and over
People
108 worldwide
Run by
Curis, Inc.
See details and how to joinNCT07271667 · EU 2025-523600-68-00
Phase 3Taking people
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Where
Madrid, Majadahonda, Pamplona, Santiago de Compostela, Sevilla
Age
18 years and over
People
170 worldwide
Run by
AbbVie
See details and how to joinNCT06428019 · EU 2024-512147-23-00
Phase 1Taking people
Study of SGR-1505 in Mature B-Cell Neoplasms
Where
L'Hospitalet de Llobregat, Madrid, Pamplona, Pozuelo de Alarcón, Salamanca
Age
18 years and over
People
98 worldwide
Run by
Schrödinger, Inc.
See details and how to joinNCT05544019 · EU 2023-505204-34-00
Phase 2Taking people
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Where
Madrid
Age
18 years and over
People
75 worldwide
Run by
AbbVie
See details and how to joinNCT04895436 · EU 2023-504599-10-00
Phase 3Not yet taking people in Spain
A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction
Where
Albacete, Alicante, Badalona, Cáceres, Córdoba, Madrid, Sevilla, Terrassa, Valencia
Age
70 years and over
People
262 worldwide
Run by
Gustave Roussy, Cancer Campus, Grand Paris
See details and how to joinNCT07082452 · EU 2025-521634-29-00
Phase 1Taking people
CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
Where
Madrid, Santander, Santiago de Compostela
Age
18 years and over
People
18 worldwide
Run by
Catapult Therapeutics
See details and how to joinNCT04704323 · EU 2024-516341-39-00
Phase 1/2Taking people
A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
Where
Barcelona, Madrid, Murcia, Salamanca, Santander, Seville, Valencia, Zaragoza
Age
18 years and over
People
37
Run by
IDP Discovery Pharma S.L.
See details and how to joinNCT05908409